56 results about "Hypertensive disorder" patented technology

Disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using combinations of compounds that alter soluble endoglin and sF1t-1 expression levels or biological activity. Also disclosed are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that increase endothelial nitric oxide synthase levels or biological activity.

The present invention provides methods and compositions related to the detection and / or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and / or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia.

The present invention relates to the use of a steroid in the manufacture of a pharmaceutical composition for use in the therapeutic or prophylactic treatment of a hypertensive disorder of pregnancy (HDP) or fetal growth retardation, said treatment comprising administering to a female mammal a steroid selected from the group consisting of: substances represented by the following formula (formula I) in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors of such substances; and mixtures of one or more of the aforementioned substances and / or precursors.

Disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using combinations of compounds that alter soluble endoglin and sFlt-1 expression levels or biological activity. Also disclosed are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that increase endothelial nitric oxide synthase levels or biological activity.

The application discloses new test panels comprising biomarkers and clinical parameters, for the prediction, diagnosis, prognosis and / or monitoring of hypertensive disorders of pregnancy and particularly preeclampsia; and related methods, uses, kits and devices.

The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.

The invention relates to a Cannabis-based pharmaceutical composition for the treatment of hypertensive disorders by submucosal delivery comprising a pharmaceutically acceptable base and an effective amount of at least one cannabinoid or endocannabinoid containing extract of a cloned hybrid of the plant Cannabis sativa, subspecies sativa and Cannabis sativa, subspecies indica of the CTSX-ISS lineage; and methods of treatment of primary and secondary hypertension, the secondary hypertension resulting from pheochromocytoma, primary hyperaldosteronism, adrenal hyperplasia, pulmonary hypertension, portal hypertension, folate deficiency hypertension, arterial hypertension or familial hypertension by administration between one and eight times per day.

A hypertensive disorder expert system comprises a blood pressure gauge module, a patient information writing module, an expert database module, a recommendation display module, and a wireless transmitting module. The data output end of the blood pressure gauge module and the data output end of the patient information writing module are connected with the data input end of the expert database module; the data output end of the expert database module is connected with the data input end of the recommendation display module and the data input end of the wireless transmitting module. According to the hypertensive disorder expert system, fluctuation of blood pressure is measured for a patient three to four times regularly each day, a special treatment scheme is made for the patient through an expert database according to the age, sex and other symptoms, medicines are reasonably allocated for use, and real-time recommendations are provided for the patient with hypertensive disorders to control the blood pressure.

Disclosed herein are methods for diagnosing a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder by measuring the level or biological activity of soluble endoglin. Also disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that alter soluble endoglin levels or biological activity.

The present description relates to a method for determining the risk of a pregnant woman developing a hypertensive disorder, more specifically gestational hyper-tension or late onset preeclampsia. The present description provides methods useful for determining risk that a pregnant individual will develop a hypertensive disorder or condition of pregnancy, such as gestational hypertension, early preeclampsia, late preeclampsia and related disorders. Several useful combinations of biochemical markers and related clinical population studies are described herein. Additionally, it is proposed herein that certain sets of biochemical markers can be used to determine risk of multiple hypertensive disorders in a single screen. The biochemical markers are PlGF, Activin A and optionally P-Selectin.

The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.

Disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using combinations of compounds that alter soluble endoglin, endothelial nitric oxide synthase, PGI2, TGF-β1, TGF-β3, activin A, BMP2, BMP7, and sFlt-1 expression levels or biological activity. Also disclosed are methods of diagnosing a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, that include the measurement of any one or more of the following: soluble endoglin, endothelial nitric oxide synthase, PGI2, TGF-β1, TGF-β3, activin A, BMP2, BMP7, and sFlt-1 expression levels or biological activity.

This invention relates generally to a method of increasing cytosolic Ca2+ levels in mammalian cells comprising contacting P2X receptor Ca2+ entry channels or any and all other Ca2+ entry channels or mechanisms on the cell with an effective amount of a small molecule, and a composition comprising the small molecule in a delivery system. The invention has broad applicability in the pharmaceutical industry as a method of treating airway diseases (such as cystic fibrosis and asthma), ailments of the lung and airways (such as those caused by common cold pathogens or allergens in allergy), kidney diseases and renal hypertensive disorders (such as polycystic kidney disease and salt-sensitive hypertension syndromes), and endocrine disorders (such as diabetes).

The invention discloses a preparation method and an application of a mouse syncytiotrophoblast microvillous membrane. The preparation method comprises the following steps of: based on mouse placenta as a raw material, separating and enriching the mouse syncytiotrophoblast microvillous membrane by mechanical separation and improved differential centrifugation methods; detecting the concentration by protein concentration quantification and identifying and quantitatively marking by polypeptide antigens of tissues. The invention further discloses the application of the mouse syncytiotrophoblast microvillous membrane prepared by the preparation method in building a mouse model with hypertensive disorder complicating pregnancy. The mouse syncytiotrophoblast microvillous membrane prepared by the method disclosed by the invention is large in yield and high in concentration, and is highly similar to human syncytiotrophoblast microvillous membrane in shape and protein marker. The mouse syncytiotrophoblast microvillous membrane can be directly used to research occurrence and development mechanism of hypertensive disorder complicating pregnancy such as preeclampsia and eclampsia as well as medical base and clinical research for developing antagonistic medicines, and can be further used to prepare an animal model of hypertensive disorder complicating pregnancy.

The invention relates to a building method of a preoperative autologus blood donation system for late trimester of pregnancy. A 300ml sealing triple bag system is adopted, the content of anticoagulants in a blood bag is increased, autologus blood of 200 ml is collected, and the anticoagulants and the blood are mixed evenly after the blood is collected and then are stored in a blood storage refrigerator of 4+ / -2.0 DEG C; the blood storage time is 15-35 days before the surgery is performed; objects with autologus blood collected are puerperae with the autologus blood donation indications, and the autologus blood donation indications are puerperae who do not have presentations of parturition signs, vaginal bleeding, growth restriction of fetuses or intrauterine hypoxia and are stable in state of illness after diseases of a cardiovascular system, diabetes, hypertensive disorder complicating pregnancy, infectious diseases and medical complications are excluded. The scientific evidence is provided for standard building of a preoperative autologus blood donation technology for late trimester of pregnancy, and therefore preoperative autologus blood donation is better applied to patients of obstetrics, the system is safer, more effective and more economical, and application and popularization of the preoperative autologus blood donation in the obstetrics are better promoted.